Targeting delivery of anti-TNFα oligonucleotide into activated colonic macrophages protects against experimental colitis

Gut

Volumn 59, Issue 4, 2010, Pages 470-479

  Zuo, Longsheng ^a   Huang, Zhen ^a   Dong, Lei ^a   Xu, Lingqing ^a   Zhu, Yi'an ^a   Zeng, Ke ^a   Zhang, Chenyu ^a   Chen, Jiangning ^a   Zhang, Junfeng ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CHITOSAN; CYTOKINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG TARGETING; FEMALE; HISTOPATHOLOGY; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOSING GASTROENTEROPATHY; WEIGHT REDUCTION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; COLITIS; COLON; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; INFLAMMATION MEDIATORS; INTESTINAL MUCOSA; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; MICE, SCID; OLIGONUCLEOTIDES, ANTISENSE; TRANSFECTION; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950792860     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.184556     Document Type: Article

References (34)

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-434 (Pubitemid 47123518)
2. Atreya R, Neurath MF. New therapeutic strategies for treatment of inflammatory bowel disease. Mucosal Immunol 2008;1:175-182 (Pubitemid 351541303)
3. Maloy KJ, Kullberg MC. IL-23 and Th17 cytokines in intestinal homeostasis. Mucosal Immunol 2008;1:339-349
4. Neurath MF, Fuss I, Pasparakis M, et al. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 1997;27:1743-1750 (Pubitemid 27302858)
5. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000;119:1148-1157
6. Han X, Benight N, Osuntokun B, et al. Tumour necrosis factor alpha blockade induces an anti-inflammatory growth hormone signalling pathway in experimental colitis. Gut 2007;56:73-81. (Pubitemid 46044891)
7. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-1405 (Pubitemid 29205403)
8. Schreiber S. Crohn's disease - infliximab, adalimumab and certolizumab-pegol: clinical value of anti-TNF-alpha treatment. Dtsch Med Wochenschr 2007;132:1770-1774 (Pubitemid 47472700)
9. Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs 2004;64:1767-1777 (Pubitemid 39215188)
10. Chan JH, Lim S, Wong WS. Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol 2006;33:533-540 (Pubitemid 43909343)
11. Pirollo KF, Rait A, Sleer LS, et al. Antisense therapeutics: from theory to clinical practice. Pharmacol Ther 2003;99:55-77. (Pubitemid 36694750)
12. Rijcken E, Krieglstein CF, Anthoni C, et al. ICAM-1 and VCAM-1 antisense oligonucleotides attenuate in vivo leucocyte adherence and inflammation in rat inflammatory bowel disease. Gut 2002;51:529-535
13. Lawrance IC, Wu F, Leite AZ, et al. A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-κB. Gastroenterology 2003;125:1750-1761 (Pubitemid 37500440)
14. Weyermann J, Lochmann D, Zimmer A. Comparison of antisense oligonucleotide drug delivery systems. J Control Release 2004;100:411-423 (Pubitemid 39572921)
15. van Vliet SJ, Saeland E, van Kooyk Y. Sweet preferences of MGL: carbohydrate specificity and function. Trends Immunol 2008;29:83-90.
16. Varshosaz J. The promise of chitosan microspheres in drug delivery systems. Expert Opin Drug Deliv 2007;4:263-273 (Pubitemid 46767627)
17. Gao S, Chen J, Xu X, et al. Galactosylated low molecular weight chitosan as DNA carrier for hepatocyte-targeting. Int J Pharm 2003;255:57-68. (Pubitemid 36369591)
18. Gao S, Chen J, Dong L, et al. Targeting delivery of oligonucleotide and plasmid DNA to hepatocyte via galactosylated chitosan vector. Eur J Pharm Biopharm 2005;60:327-334 (Pubitemid 40922830)
19. Dong L, Gao S, Diao H, et al. Galactosylated low molecular weight chitosan as a carrier delivering oligonucleotides to Kupffer cells instead of hepatocytes in vivo. J Biomed Mater Res A 2008;84:777-784 (Pubitemid 351237795)
20. Santucci L, Agostini M, Bruscoli S, et al. GITR modulates innate and adaptive mucosal immunity during the development of experimental colitis in mice. Gut 2007;56:52-60. (Pubitemid 46044889)
21. Corazza N, Eichenberger S, Eugster HP, et al. Nonlymphocyte-derived tumor necrosis factor is required for induction of colitis in recombination activating gene (RAG)2(-/-) mice upon transfer of CD4(+)CD45RB(hi) T cells. J Exp Med 1999;15;1479-1492
22. Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995;182:1281-1290
23. Morrissey PJ, Charrier K, Braddy S, et al. CD4+T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4+ T cells. J ExpMed 1993;178:237-244
24. Kihara N, de la Fuente SG, Fujino K, et al. Vanilloid receptor-1 containing primary sensory neurones mediate dextran sulphate sodium induced colitis in rats. Gut 2003;52:713-719 (Pubitemid 36528875)
25. Shi F, Hoekstra D. Effective intracellular delivery of oligonucleotides in order to make sense of antisense. J Control Release 2004;97:189-209. (Pubitemid 38759477)
26. Gao D, Wagner AH, Fankhaenel S, et al. CD40 antisense oligonucleotide inhibition of trinitrobenzene sulphonic acid induced rat colitis. Gut 2005;54:70-77 (Pubitemid 40007220)
27. Lv H, Zhang S, Wang B, et al. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 2006;114:100-109 (Pubitemid 44128621)
28. Pack DW, Hoffman AS, Pun S, et al. Design and development of polymers for gene delivery. Nat Rev Drug Discov 2005;4:581-593 (Pubitemid 40975711)
29. Hashida M, Nishikawa M, Yamashita Y, et al. Cell-specific delivery of genes with glycosylated carriers. Adv Drug Deliv Rev 2001;52:187-196 (Pubitemid 33097545)
30. Katsuyama R, Morioka A, Oka S, et al. Expression of macrophage asialoglycoprotein-binding protein is induced through MAPK classical pathway. Biochem Biophys Res Commun 2001;280:1269-1273 (Pubitemid 32917780)
31. Zhang X, Mosser DM. Macrophage activation by endogenous danger signals. J Pathol 2008;214:161-178 (Pubitemid 351160154)
32. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008;8:958-969
33. van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut 1997;40:443-448 (Pubitemid 27204920)
34. Myers KJ, Murthy S, Flanigan A, et al. Antisense oligonucleotide blockade of tumor necrosis factor-alpha in two murine models of Colitis. J Pharmacol Exp Ther 2003;304:411-424 (Pubitemid 36008955)